Imaging Studies of Kidney Cancer Using 18F-VM4-037
Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Background:
- The drug 18F-VM4-037 is being tested for use in cancer imaging studies. It may help tumor
tissue show up more clearly during scans. Researchers want to see how well it works for scans
for people who have kidney cancer.
Objectives:
- To test the safety and effectiveness of 18F-VM4-037 during imaging studies of kidney
cancer.
Eligibility:
- Adults at least 18 years of age with kidney cancer that will be treated with surgery.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected.
- Participants will have two positron emission tomography (PET) scans of their kidneys.
They will have the scans before and after receiving an injection of 18F-VM4-037. The
scans will take about 2 hours to complete.
- About 3 weeks after the PET scans, participants will provide tumor tissue samples from
their kidneys.
- This is a scanning study only. Treatment will not be provided as part of this study.